Research programme: gene therapies - Tenaya Therapeutics
Latest Information Update: 11 Sep 2024
At a glance
- Originator Tenaya Therapeutics
- Class Cardiovascular therapies; Gene therapies; Heart failure therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Dilated cardiomyopathy; Heart failure; Hypertrophic cardiomyopathy
Most Recent Events
- 14 Aug 2024 Early research in Dilated cardiomyopathy in USA (Parenteral) (Tenaya Therapeutics pipeline, August 2024)
- 14 Aug 2024 Early research in Heart failure in USA (Parenteral) (Tenaya Therapeutics pipeline, August 2024)
- 14 Aug 2024 Early research in Hypertrophic cardiomyopathy in USA (Parenteral) (Tenaya Therapeutics pipeline, August 2024)